Pfizer and Merck reported earnings that highlight their differing dividend and growth profiles for 2026. Pfizer offers a strong 6.58% dividend yield backed by solid earnings and a focus on cost savings and new drug launches, prioritizing income over buybacks. Merck, with a lower 2.74% yield, shows faster revenue growth driven by key drugs like KEYTRUDA but faces challenges like patent risks and rising debt. Investors seeking reliable income may prefer Pfizer, while growth-oriented investors might lean toward Merck.
In the first half of 2026, smart beta strategies showed mixed results, with momentum and low-volatility funds lagging, while dividend growth funds struggled due to rising yields. However, funds emphasizing companies with strong free cash flow and hig...
Pfizer is trading at a forward P/E of 9 and offers a 6.58% dividend yield, with a 24/7 Wall St. price target of $32.92, implying a 25.76% upside from its current $26.18 price. The company’s non-COVID products are growing steadily, offsetting declines...
Pfizer is navigating a transitional phase aiming for growth by 2029, maintaining its dividend payout to support financial stability despite patent losses and reduced COVID revenues. The company’s dividend payout ratio aligns with management’s long-te...
